Journal
IRANIAN RED CRESCENT MEDICAL JOURNAL
Volume 15, Issue 6, Pages 526-528Publisher
KOWSAR PUBL
DOI: 10.5812/ircmj.4557
Keywords
Lead; Hypertension; Prazosin
Categories
Ask authors/readers for more resources
Introduction: Chronic lead exposure is known to be a risk factor for hypertension (HTN). No specific medication is recommended for the treatment of lead-induced hypertension (LIHTN). Case Presentation: Our patient was a male admitted with the chief complaint of chronic abdominal pain. His whole blood lead level was reported to be 1961 mu g/L. He also mentioned a previous history of HTN managed by propranolol (10 mg, TDS). He discharged himself by giving written consent and 19 days later, he was re-admitted due to high blood pressure of 220/140 mmHg. His Blood pressure (BP) was decreased to 180/110 mmHg with sublingual captopril; but, in maintenance therapy, higher doses of captopril could not further decrease BP. Amlodipine was tried which was discontinued due to the patient intolerance. Prazosin was then administered in gradual increasing doses up to 1 mg twice a day and captopril was tapered. Conclusions: We would like to suggest that LIHTN may better be managed by alpha blockers compared with converting enzyme inhibitors
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available